ARTICLE | Clinical News
CM-24: Ph I terminated
March 29, 2017 12:56 AM UTC
Merck terminated an open-label, dose-escalation, U.S. and Israeli Phase I trial evaluating CM-24 in combination with Keytruda pembrolizumab in 27 patients. The company said CM-24 showed no signs of ef...
BCIQ Company Profiles